EASD 2023 - EASD/ADA consensus report on hyperglycaemic crises in adult patients with diabetes @EASDiabetes

Uploaded October 2023 | Updated September 2026, 3 days ago

Irl Hirsch, Gian Paolo Fadini and Ketan Dhatariya laid out the rationale for putting together the new EASD/ADA consensus report on hyperglycaemic crises in adult patients with #diabetes. They highligted the danger of diabetic ketoacidosis (DKA) and differences in how #hyperglycaemia and DKA get treated in different countries.
#easd2023 #hyperglycemia

EASD 2023 - EASD/ADA consensus report on hyperglycaemic crises in adult patients with diabetes

EASD 2023 - Peter Thorn and Sushil Rane explaining the relationship between diabetes and the brain

EASD 2025: Results from the SOUL Trial - The Cardiologists Perspective

Meet the EASD Early Career Academy - Introducing Pierre Larraufie

#EASD2022 Interview with the EASD-Lilly Centennial Anniversary Prize Lecturerer Matthias Tschöp

9th ECA Webinar: How to DiRECT understanding of t2d into a major advance in clinical care

EASD 2023 - What is the Hypo-RESOLVE project?

EASD 2024 Exlusive Interview with Dr. Rodica Busui - Camillo Golgi Award Winner

EASD 2024 - The Future of Type 1 Diabetes - Will We See Prevention or Cure?

EASD 2023 - Interview with Roman Hovorka, EASD-Novo Nordisk Foundation Diabetes Prize for Excellence

EASD 2025: Impacting Lives of People with Diabetes in Resource Constrained Settings

$Best of EASD 2025 by the EASD Early Career Academy – featuring Dr. Michael Leutner In the seventh episode of our highlights from the EASD Annual Meeting 2025 in Vienna series, Dr. Michael Leutner from the Medical University of Vienna, Austria shares insights from the SOUL Trial which investigated the effects of oral semaglutide on cardiovascular outcomes in people with type 2 diabetes. Michael Leutner explains the design and baseline characteristics of the SOUL Trial and presents the main outcomes regarding heart failure and peripheral artery disease. Main trial outcomes for heart failure include: - Oral semaglutide reduces heart failure events or cardiovascular death in people with type 2 diabetes with a history of heart failure compared to placebo. - Benefits were strongly observed in trial participants with heart failure with preserved ejection fraction (HFpEF), with no safety concerns identified in this group - Positive effects were observed regardless of the high baseline use of SGLT-2 inhibitors or mineralocorticoid receptor antagonists - No increased risk of serious adverse events Main trial outcomes for peripheral artery disease include: - Oral semaglutide reduces major adverse limb events, including acute limb ischemia and chronic limb ischemia #easd2025 #Diabetes #Type2Diabetes #HeartFailure #CardiovascularDisease #ClinicalTrial #DiabetesResearch$